Compare RLI & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RLI | KRYS |
|---|---|---|
| Founded | 1965 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 7.8B |
| IPO Year | 1994 | 2017 |
| Metric | RLI | KRYS |
|---|---|---|
| Price | $61.14 | $259.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $66.00 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 701.3K | 260.4K |
| Earning Date | 04-22-2026 | 05-18-2026 |
| Dividend Yield | ★ 4.28% | N/A |
| EPS Growth | 16.84 | ★ 128.00 |
| EPS | 4.37 | ★ 6.84 |
| Revenue | ★ $1,882,448,000.00 | $389,130,000.00 |
| Revenue This Year | N/A | $40.88 |
| Revenue Next Year | $3.53 | $35.16 |
| P/E Ratio | ★ $14.15 | $37.15 |
| Revenue Growth | 6.33 | ★ 33.94 |
| 52 Week Low | $55.80 | $123.03 |
| 52 Week High | $81.79 | $298.30 |
| Indicator | RLI | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 48.96 | 44.51 |
| Support Level | $60.44 | $255.65 |
| Resistance Level | $65.43 | $293.60 |
| Average True Range (ATR) | 1.30 | 11.12 |
| MACD | -0.02 | -2.10 |
| Stochastic Oscillator | 36.86 | 20.44 |
RLI Corp underwrites property and casualty insurance through its subsidiaries. The company offers insurance coverage in the specialty admitted market, where the products are designed for special risks. It also offers products in the excess and surplus markets, which provides an alternative for customers with risks or loss exposures that generally cannot be written in the standard admitted market. RLI distributes property and casualty insurance through its wholly-owned branch offices that market to wholesale and retail producers. The company's insurance operation segments include Casualty, Property, and Surety and it derives a majority of its revenue from the Casualty segment.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.